Tissue factor pathway inhibitor and the current concept of blood coagulation
- PMID: 7647225
- DOI: 10.1097/00001721-199506001-00002
Tissue factor pathway inhibitor and the current concept of blood coagulation
Abstract
Tissue factor pathway inhibitor (TFPI) is a multivalent, Kunitz-type plasma proteinase inhibitor that regulates tissue factor-induced coagulation. TFPI directly inhibits activated factor X and, in a factor Xa-dependent manner, produces feedback inhibition of the factor VIIa/tissue factor catalytic complex. The properties of this inhibitor help explain the clinical need for 'extrinsic' and 'intrinsic' coagulation pathways and have led to a reformulation of the coagulation cascade. In the revised hypothesis, factor VIIa/tissue factor is responsible for the initiation of coagulation but, owing to TFPI-mediated feedback inhibition, amplification of the procoagulant response though the actions of factor VIII, IX and XI is required for sustained haemostasis.
Similar articles
-
Tissue factor pathway inhibitor and the revised theory of coagulation.Annu Rev Med. 1995;46:103-12. doi: 10.1146/annurev.med.46.1.103. Annu Rev Med. 1995. PMID: 7598447 Review.
-
[Tissue factor pathway inhibitors].Pol Merkur Lekarski. 2002 Jul;13(73):66-9. Pol Merkur Lekarski. 2002. PMID: 12362512 Review. Polish.
-
Tissue factor residues Lys165 and Lys166 are essential for rapid formation of the quaternary complex of tissue factor.VIIa with Xa.tissue factor pathway inhibitor.Biochemistry. 1995 Aug 29;34(34):10867-71. doi: 10.1021/bi00034a020. Biochemistry. 1995. PMID: 7662667
-
Tissue factor pathway inhibitor: new insights into an old inhibitor.Semin Thromb Hemost. 2012 Mar;38(2):129-34. doi: 10.1055/s-0032-1301410. Epub 2012 Feb 8. Semin Thromb Hemost. 2012. PMID: 22422327 Review.
-
Role of tissue factor pathway inhibitor in the regulation of tissue factor-dependent blood coagulation.Cardiovasc Drug Rev. 2002 Winter;20(1):67-80. doi: 10.1111/j.1527-3466.2002.tb00083.x. Cardiovasc Drug Rev. 2002. PMID: 12070535 Review.
Cited by
-
Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants.Blood. 2005 May 15;105(10):3902-9. doi: 10.1182/blood-2004-11-4435. Epub 2005 Jan 27. Blood. 2005. PMID: 15677561 Free PMC article.
-
Tissue factor pathway inhibitor is an inhibitor of factor VII-activating protease.J Thromb Haemost. 2012 Jun;10(6):1165-71. doi: 10.1111/j.1538-7836.2012.04712.x. J Thromb Haemost. 2012. PMID: 22449009 Free PMC article.
-
Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor.J Thromb Thrombolysis. 2004 Dec;18(3):193-7. doi: 10.1007/s11239-005-0345-6. J Thromb Thrombolysis. 2004. PMID: 15815881
-
The hemostatic defect of cardiopulmonary bypass.J Thromb Thrombolysis. 2003 Dec;16(3):129-47. doi: 10.1023/B:THRO.0000024051.12177.e9. J Thromb Thrombolysis. 2003. PMID: 15087599 Review.
-
Polyphosphate: a new player in the field of hemostasis.Curr Opin Hematol. 2014 Sep;21(5):388-94. doi: 10.1097/MOH.0000000000000069. Curr Opin Hematol. 2014. PMID: 25010799 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous